《新股表現》微創腦科學(02172.HK)暗盤高開1.5%報25元
根據輝立交易平臺顯示,明天掛牌的微創腦科學(02172.HK)暗盤高開1.5%報25元欠承接,掉頭低見23.1元,現報23.6元,較上市價24.64元,低4.2%,成交1.1萬股。
由微創醫療(00853.HK)分拆的微創腦科學是內地神經介入醫療器械公司,致力於向醫生及患者提供創新解決方案。是次上市以每股24.64元發售1,370萬股,並已引入Harvest及新華網(603888.SH)爲基石投資者合共認購890.5萬股;10%公開發售獲逾44倍超購,認購一手中籤率僅4.88%;料集資淨額約2.78億元,主要用於研發出血性腦卒中、腦動脈粥樣硬化狹窄與急性缺血性腦卒中治療和通路產品;將相關產品商業化;用於擴張製造設施以擴大生產規模;用於擴大全球影響力,以及透過戰略收購、投資、合作或該等策略結合以優化產品組合。上市聯席保薦人分別爲摩通及中金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.